[go: up one dir, main page]

WO1995032720A1 - Composition pour traiter des troubles gastro-intestinaux - Google Patents

Composition pour traiter des troubles gastro-intestinaux Download PDF

Info

Publication number
WO1995032720A1
WO1995032720A1 PCT/AU1995/000319 AU9500319W WO9532720A1 WO 1995032720 A1 WO1995032720 A1 WO 1995032720A1 AU 9500319 W AU9500319 W AU 9500319W WO 9532720 A1 WO9532720 A1 WO 9532720A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
lactobacillus
bismuth
composition
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU1995/000319
Other languages
English (en)
Inventor
Gregory Murray Winn
John Benjamin Borushek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HYBRID SCIENTIFIC Pty Ltd
Original Assignee
HYBRID SCIENTIFIC Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HYBRID SCIENTIFIC Pty Ltd filed Critical HYBRID SCIENTIFIC Pty Ltd
Priority to AU25578/95A priority Critical patent/AU2557895A/en
Publication of WO1995032720A1 publication Critical patent/WO1995032720A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients

Definitions

  • This invention relates to compositions and methods for the symptomatic treatment or amelioration of gastrointestinal disease induced by pathogenic infection.
  • Gastrointestinal disorders may arise in the upper or lower gastrointestinal tract or both.
  • causes of gastrointestinal disorders include genetic, physiological, environmental and psychogenic factors. In view of this, the diagnosis and management of such disorders can be exceptionally difficult.
  • ulcers are those which may be generally categorised as causing gastritis and more particularly peptic ulcer disease (especially in the lower gastrointestinal tract).
  • Gastritis is, typified by inflammation of the stomach mucosa. In practice this disorder manifests itself in symptoms such as dyspepsia, indigestion, heartburn and excessive reflux disorders.
  • Peptic ulcers on the other hand manifest themselves as lesions of the gastrointestinal tract lining and are often characterised by loss of tissue due to the action of digestive acids and pepsin. They are thought to be caused either by gastric hyposecretion or more often by decreased resistance of the gastric lining to digestive acids and pepsin. Approximately twenty per cent of the world's population suffers from these chronic disease states.
  • sufferers obtained temporary symptomatic relief from the disease states caused by Helicobacter pylori with anti-acid drugs.
  • This form of treatment alleviates the gastritis but does not remove the underlying causative agent, viz the bacteria.
  • healing is often followed by a relapse of the disease after about 6-12 weeks resulting in inflammation often leading to ulcers again.
  • patients must stay on the anti-acid treatment for life otherwise the gastritis will often return.
  • antibiotic combinations include tinidazole, amoxicillin and metronidazole.
  • Antibiotic combinations are a powerful form of treatment which generally kill the helicobacter in situ after which the gastritis goes away naturally.
  • side effects of such combinations include nausea, devastation of the microflora in the gastrointestinal tract leading to a microflora imbalance and occasionally diarrhoea.
  • treatment with an appropriate antibiotic combination will clear the pathogen, recurrence of infection occasionally >ccurs within one to six months following drug therapy.
  • devastion of the microflora in the gastrointestinal tract often leaves the patient susceptible to other forms of bacterial attack.
  • Bismuth salts Such compounds have been used to treat various Helicobacter induced diseases, including gastritis and peptic ulcers. Bismuth therapy is as effective as anti-acids, but much cheaper.
  • i_ vitro Helicobacter pylori is inhibited by bismuth compounds at concentrations of 25 mg/L or less. In biopsies taken two hours after ingestion of bismuth compounds marked changes are evident in the Helicobacter pylori bacteria and in their relationship to a patient's epithelium. Many of the organisms appear irregular or fragmented or show structural degradation and deposits of electron- dense material are often present on the external surface and to a lesser extent, within the damaged bacteria.
  • compositions comprising bismuth and bacteria from the genus Lactobacillus species and or Bifidobacterium are effective in treating or ameliorating gastrointestinal disorders induced by pathogenic agents.
  • the present invention provides a substantially natural cure or affords lower relapse rates of gastritis and peptic ulcer disease as compared to other methods of treatment.
  • the present invention consists in a composition effective in treating or ameliorating gastrointestinal disorders caused by a pathogenic agent, the said composition comprising;
  • compositions of the present invention are employed to treat gastrointestinal disorders caused by Helicobacter bacteria colonising the gastrointestinal tract. More preferably the present invention is used to treat gastrointestinal disorders caused by Helicobacter pylori.
  • the bismuth salt is preferably administered as a pharmaceutically acceptable salt.
  • Bismuth salts that may be used in the present invention include; for example, bismuth aluminate, bismuth subcarbonate, bismuth subcitrate, bismuth citrate, bismuth subgalate, bismuth subnitrate, bismuth tartrate, bismuth subsalicylate, tripotassium dicitrato bismuthate or any other colloidal or soluble bismuth salt.
  • the pharmaceutically acceptable bismuth salt is bismuth citrate, bismuth subcitrate, bismuth tartrate, bismuth subsalicylcate or tripotassium dicitrate bismuthate.
  • Bismuth salts are preferably administered in dose amounts of between 1 and 5000 mg and more preferably between about 50 and 1500 mg per dosage form depending on the age and weight of the person and severity of the gastrointestinal disorder that needs to be treated. More preferably the dose is between 100 and 500 mg per dosage form.
  • a typical dosage amount of Bismuth subcitrate effective in treating Helicobacter pylori infection in an adult human would be about 100-200 mg administered two to three times daily.
  • the most common recommended therapeutic Lactobacillus are Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus bul ⁇ aricus.
  • Lactobacillus acidophillus should not be mixed with Lactobacillus bul ⁇ aricus. Lactobacillus fermentum, Lactobacillus helveticus. or Lactobacillus plantarium.
  • Bifidobacterium bacteria that may be used in the present invention include: Bifidobacterium bifidum. Bifidobacterium adolescentis. Bifidobacterium breve. Bifidobacterium infantis and Bifidobacterium longum.
  • the bacterial species employed in the composition is either Lactobacillus acidophilus or Bifidobacterium bifidum of both.
  • the bacteria may be employed in either a freeze dried or live culture form.
  • the bacterial is provided in a freeze dried form.
  • the bacteria is preferably provided as a live culture.
  • Gastrointestinal disorders that may be treated by the present invention include but are not limited to; non-ulcerated disorders such as chronic or atrophic gastritis; non-ulcerative dyspepsia; oesophogeal reflux disorders; gastric motility disorders; peptic ulcer disease such as duodenal ulcers, gastric ulcers, jejunal ulcers or gastric cancer.
  • the composition of the present invention will normally be administered as a pharmaceutical composition in combination with a pharmaceutically acceptable carrier therefore.
  • the composition may have added thereto other pharmacological active compounds known to be useful in treating gastrointestinal disorders.
  • the composition may include antacid compounds such as pH buffering agents that are capable of neutralising acid pH build up (eg magnesium trisilicate or aluminium hydroxide gel); H 2 receptor antagonists such as omeprazole, cimetidine, or ranitidine that suppress acid production by the cells of the stomach mucosa; rafting compounds that increase the viscocity of the gastrointestinal content particularly in the stomach; mucus membrane stomach protectants such as sucralfate; or mucilaginous agents or dispersants that would be effective in dispersing and settling the stomach, reducing gastric reflux and coating the stomach and intestines with the composition.
  • antacid compounds such as pH buffering agents that are capable of neutralising acid pH build up (eg magnesium trisilicate or aluminium hydroxide gel); H 2 receptor antagonist
  • the present invention may also include antiulcer agents or adhesion inhibitors of helicobacter pylori comprising for example fucoidan or a phaeophyceae chordariales nemacystus extract containing fucoidan where the fucoidan is optionally degraded.
  • Fucoidan is an extract of red or brown algae that prevents ulcers on the gastric mucosa by inhibiting adhesion of helicobacter pylori to the gastric mucosa.
  • the composition may additionally include one or more antimicrobial agents.
  • an antimicrobial agent is included in the composition then preferably the Lactobacillus and/or Bifidobacterium bacteria are encapsulated in slow release microcapsules which are degraded by acid pH. Any means of microencapsulation known in the art may be employed for this purpose. Desirably, both the bismuth salt and the bacteria are encapsulated in slow release microcapsules. In this form the antimicrobial agent is able to effectively inhibit helicobacter pylori activity prior to the release of the composition of the present invention.
  • Antimicrobial agents which may be employed in such a composition include; gentamycin, neomycin, kanamycin, streptomycin, erythromycin, clindamycin, rifampin, penicillin, ampicillin, amoxycillin, bacitracin, polymyxin, tetracyclin, chlortetracycline, oxyteracycline, doxycycline, cephalexin, cephalothin, chloramphenicol, sulphonamides, nitrofurazone, nitrofuractoin, furozolidone, metronidazole, tinidazole, nimorazole and mixtures thereof.
  • Highly preferred antimicrobial agents include erythromycin, penicillin, ampicillin, amoxycillin, doxycycline, nitrofuratoin, metranidazole and tinidazole.
  • composition of the invention is not microencapsulated then it is desirable to minimise or avoid the simultaneous presence of the present invention when used in combination with an antimicrobial agent. This may for example be achieved by staggering the administration of these agents.
  • the antimicrobial agent may be administered via an alternative means to oral administration. Any means which would facilitate such administration may be employed.
  • the present invention includes an antimicrobial agent, then that agent is preferably provided in a dosage of about 100 to 10000 mg per day and preferably about 100 and 1000 mg per day depending on the age and weight of the person and the severity of the gastrointestinal disorder to be treated.
  • the specific preferred quantity of antimicrobical agent, and the duration of treatment with the composition (when containing such an agent) will, in addition to other factors depend upon the particular antimicrobial used and its pharmacology. Further, the speed of degradation of the slow release microcapsules should be varied to account for the pharmacological effect of the antimicrobial and the duration of effect which the selected antimicrobial has on the patient.
  • compositions of the present invention will be made in a dosage unit form appropriate to the desired mode of administration.
  • a dosage unit form appropriate to the desired mode of administration.
  • a dosage unit form appropriate to the desired mode of administration.
  • compositions may be in a form suitable for oral use.
  • aqueous or oily suspensions dispensable powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known in the art. Further, such compositions may contain one or more agents selected from a group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide a pharmaceutical elegant and palatable preparation.
  • Tablets may for example contain the composition in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for manufacture of such tablets.
  • excipients may be inert diluents, for example lactose, calcium phosphate, calcium carbonate, sodium phosphate; granulating or disintegrating agents, for example maze, starch, or alginic acid; binding agents such as starch, gelatine or acacia; and lubricating agents such as magnesium stearate or stearic acid.
  • Such tablets may be uncoated or they may be coated by known techniques to prolong dispersal and absorption into the gastrointestinal tract thereby providing a sustained action for a longer period.
  • Formulations for oral use may also be presented as hard gelatine capsules wherein the active ingredient is mixed with an inert solic diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active ingredient is mixed with an oil medium such as arachis oil or liquid paraffin or olive oil.
  • an inert solic diluent for example, calcium carbonate, calcium phosphate or kaolin
  • an oil medium such as arachis oil or liquid paraffin or olive oil.
  • Aqueous suspensions may for example contain the active ingredients in admixture with excipients suitable for the manufacture of such suspensions.
  • Excipients suitable for use in the invention might include for example suspending agents such as sodium carboxymethyl cellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, mucillagenous gums (eg plant gum); dispersing or wetting agents such as naturally occurring phosphatides or condensation products of an alkaline oxide with fatty acid or for example polyoxyethylene stearate or condensation products of ethylene oxide with long chain aliphatic alcohols.
  • the composition may also contain one or more preservatives, colouring agents, flavouring agents or sweetening agents.
  • Syrups and elixirs may also be formulated with sweetening agents, for example glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavouring and colouring agents.
  • composition of this invention may be used by administering the composition from 1 to 10 times per day or every alternate day for a period of between 3 to 28 days.
  • the frequency of administration will largely depend upon the specific bismuth salts used, the physicological state and viability of the bacteria, whether the composition contains such additives as antimicrobial agents, the concentration or amounts in which the components are included in the composition, the nature and severity of the condition to be treated, and the nature of any concurrent therapy (if any).
  • a food supplement effective in treating or ameliorating gastrointestinal disorders caused by a pathogenic agent comprising:
  • the food supplement is provided in a yoghurt or ice cream mixture.
  • the food supplement may be combined with any other food base that will mix with the supplement.
  • the bacteria in the composition is preferably Lactobacillus acidophillus and or Bifidobacterium bifidum.
  • H. pylori Helicobacter pylori
  • a formulation was prepared containing bismuth subcitrate (500mg) and Lactobacillus acidophilus (750 mg) as freeze dried viable bacteria.
  • the composition was mixed and provided in capsules with a base of 1 % by weight of whey, and microcrystalline cellulose.
  • composition according to the present invention is made comprising:
  • composition is made by simply admixing the components and then pressing them into tablets using conventional methods.
  • the composition is then administered to a human subject having gastritis or peptic ulcer lesions three times daily for fourteen days.
  • composition according to the present invention is made comprising:
  • composition is made by simply admixing the components and then pressing them into tablets using conventional methods.
  • the composition is then administered to a human subject having gastritis or peptic ulcer lesions, two or three times daily for two to three weeks.
  • composition according to the present invention is prepared comprising:
  • composition is made by simply admixing the components and adding them to a capsule using convention methods. The composition is then administered to a human patient suffering from gastritis or peptic ulcer lesions, three times daily for two weeks.
  • a composition according to the present invention is prepared comprising: Bismuth carbonate 0.5 gm
  • Lactobacillus acidophilus 0.4 gm
  • composition is made by simply admixing the components and then pressing them into a tablet using conventional methods.
  • the composition is then administered to a human patient suffering from gastritis or peptic ulcer lesions three times daily for two weeks
  • composition according to the present invention is prepared comprising: Bismuth sub-citrate 0.6 gm
  • composition is made by simply admixing the components and then pressing them into a tablet using conventional methods.
  • the composition is then administered to a human patient suffering from gastritis or peptic ulcer lesions three times daily for two weeks.
  • composition according to the present invention is prepared comprising:
  • composition is made by simply admixing the components and then pressing them into a tablet using conventional methods.
  • the composition is then administered to a human patient suffering from gastritis or peptic ulcer lesions three times daily for two weeks
  • composition according to the present invention is prepared comprising:
  • composition is made by simply admixing the components and then pressing them into a tablet using conventional methods. The composition is then administered to a human patient suffering from gastritis or peptic ulcer lesions three times daily for two weeks.
  • composition according to the present invention is prepared comprising:
  • composition is made by simply admixing the components and then pressing them into a tablet using conventional methods.
  • the composition is then administered to a human patient suffering from gastritis or peptic ulcer lesions three times daily for two weeks
  • composition according to the present invention is prepared comprising:
  • Lactobacillus acidophilus 0.2 gm
  • composition is made by simply admixing the components and then pressing them into a tablet using conventional methods.
  • the composition is then administered to a human patient suffering from gastritis or peptic ulcer lesions three times daily for two weeks
  • composition according to the present invention is prepared comprising: Bismuth sub-citrate 0.12 gm
  • composition is made by simply admixing the components and then pressing them into a tablet using conventional methods.
  • the composition is then administered to a human patient suffering from gastritis or peptic ulcer lesions three times daily for two weeks
  • composition according to the present invention is prepared comprising:
  • composition is made by simply admixing the components and then pressing them into a tablet using conventional methods.
  • the composition is then administered to a human patient suffering from gastritis or peptic ulcer lesions three times daily for two weeks
  • a food supplement according to the present invention is prepared comprising:
  • the food supplement is made by simply admixing the components.
  • the supplement is then ingested by a human patient suffering from gastritis or peptic ulcer lesions three times daily for two weeks.
  • a food supplement according to the present invention is prepared comprising:
  • the food supplement is made by simply admixing the components.
  • the supplement is then ingested by a human patient suffering from gastritis or peptic ulcer lesions three times daily for two weeks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne des compositions et des méthodes de traitement symptomatique de troubles gastro-intestinaux dus à des infections par des agents pathogènes. La composition contient: (i) un sel de bismuth en une quantité suffisante pour traiter le trouble gastro-intestinal en question et (ii) au moins une bactérie choisie parmi les bactéries du genre Lactobacillus et/ou Bidobacterium.
PCT/AU1995/000319 1994-05-30 1995-05-30 Composition pour traiter des troubles gastro-intestinaux Ceased WO1995032720A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25578/95A AU2557895A (en) 1994-05-30 1995-05-30 Composition for treating gastrointestinal disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM5968 1994-05-30
AUPM5968A AUPM596894A0 (en) 1994-05-30 1994-05-30 Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders

Publications (1)

Publication Number Publication Date
WO1995032720A1 true WO1995032720A1 (fr) 1995-12-07

Family

ID=3780543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1995/000319 Ceased WO1995032720A1 (fr) 1994-05-30 1995-05-30 Composition pour traiter des troubles gastro-intestinaux

Country Status (2)

Country Link
AU (2) AUPM596894A0 (fr)
WO (1) WO1995032720A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702729A (en) * 1995-12-07 1997-12-30 The Procter & Gamble Company Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria
US5744168A (en) * 1995-12-07 1998-04-28 The Procter & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
WO1998023272A1 (fr) * 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions et procedes pour le traitement de troubles gastro-intestinaux
US5827543A (en) * 1995-12-07 1998-10-27 The Procter & Gamble Company Methods and compositions for the prevention and treatment of urogenital disorders
US5882686A (en) * 1995-12-07 1999-03-16 The Procter & Gamble Company Methods for the prevention and treatment of urogenital disorders
WO1999042568A1 (fr) * 1998-02-20 1999-08-26 Mendes S.R.L. Utilisation d'une bacterie dotee de l'arginine deiminase pouvant provoquer l'apoptose et/ou reduire une reaction inflammatoire, et compositions pharmaceutiques ou dietetiques contenant ladite bacterie
US6051604A (en) * 1995-12-07 2000-04-18 The Proctor & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US6183776B1 (en) 1996-01-08 2001-02-06 Astra Aktiebolag Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
WO1995034292A3 (fr) * 1994-06-14 2001-12-06 Recordati Chem Pharm Composes stabilises et biologiquement actifs contenus dans des microgranules enrobees pouvant etre mises en suspension dans des liquides alimentaires
WO2002005829A3 (fr) * 2000-07-17 2002-05-02 Hansens Lab Procede permettant de reduire les changements dans la flore gastro-intestinale nuisibles du point de vue ecologique intervenus chez des patients suivant un traitement medicamenteux
WO2009134948A1 (fr) * 2008-05-01 2009-11-05 The Procter & Gamble Company Procédés et kits destinés au traitement de troubles inflammatoires de l’intestin
EP1941888A4 (fr) * 2005-09-26 2012-05-30 Ako Kasei Co Ltd Procédé d'inhibition de la prolifération et de la migration de helicobacter pylori

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6779M (fr) * 1967-07-19 1969-03-10
FR6929M (fr) * 1967-11-29 1969-05-05
FR2566664A1 (fr) * 1984-06-29 1986-01-03 Nelson Res & Dev Composition utile au traitement de la diarrhee contenant du dextromethorphan

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6779M (fr) * 1967-07-19 1969-03-10
FR6929M (fr) * 1967-11-29 1969-05-05
FR2566664A1 (fr) * 1984-06-29 1986-01-03 Nelson Res & Dev Composition utile au traitement de la diarrhee contenant du dextromethorphan

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034292A3 (fr) * 1994-06-14 2001-12-06 Recordati Chem Pharm Composes stabilises et biologiquement actifs contenus dans des microgranules enrobees pouvant etre mises en suspension dans des liquides alimentaires
US6051604A (en) * 1995-12-07 2000-04-18 The Proctor & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US5744168A (en) * 1995-12-07 1998-04-28 The Procter & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US5827543A (en) * 1995-12-07 1998-10-27 The Procter & Gamble Company Methods and compositions for the prevention and treatment of urogenital disorders
US5882686A (en) * 1995-12-07 1999-03-16 The Procter & Gamble Company Methods for the prevention and treatment of urogenital disorders
US5702729A (en) * 1995-12-07 1997-12-30 The Procter & Gamble Company Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria
US6183776B1 (en) 1996-01-08 2001-02-06 Astra Aktiebolag Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
WO1998023272A1 (fr) * 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions et procedes pour le traitement de troubles gastro-intestinaux
WO1999042568A1 (fr) * 1998-02-20 1999-08-26 Mendes S.R.L. Utilisation d'une bacterie dotee de l'arginine deiminase pouvant provoquer l'apoptose et/ou reduire une reaction inflammatoire, et compositions pharmaceutiques ou dietetiques contenant ladite bacterie
AU754483B2 (en) * 1998-02-20 2002-11-14 Actial Farmaceutica S.R.L. Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria
US6572854B1 (en) 1998-02-20 2003-06-03 Mendes S.R.L. Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria
US7147847B2 (en) 1998-02-20 2006-12-12 Vsl Pharmaceuticals, Inc. Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria
WO2002005829A3 (fr) * 2000-07-17 2002-05-02 Hansens Lab Procede permettant de reduire les changements dans la flore gastro-intestinale nuisibles du point de vue ecologique intervenus chez des patients suivant un traitement medicamenteux
EP1941888A4 (fr) * 2005-09-26 2012-05-30 Ako Kasei Co Ltd Procédé d'inhibition de la prolifération et de la migration de helicobacter pylori
WO2009134948A1 (fr) * 2008-05-01 2009-11-05 The Procter & Gamble Company Procédés et kits destinés au traitement de troubles inflammatoires de l’intestin

Also Published As

Publication number Publication date
AU2557895A (en) 1995-12-21
AUPM596894A0 (en) 1994-06-23

Similar Documents

Publication Publication Date Title
RU2685226C2 (ru) Композиция, содержащая пробиотические бактерии, способная восстанавливать барьерный эффект желудка, утраченный в процессе фармакологического лечения повышенной кислотности желудка
US5229137A (en) Methods and pharmaceutical compositions for treating episodic heartburn
KR960016582B1 (ko) 위장장해의 치료 및 예방용 약제학적 조성물
RU2617952C2 (ru) Композиция, содержащая N-ацетилцистеин в сочетании с пробиотическими бактериями, способная восстанавливать собственный барьерный эффект желудка, который утрачивается во время фармалогического лечения желудочной гиперацидности
JP2733849B2 (ja) 胃腸障害治療のための改良された方法
US20120053239A1 (en) Treatment for intestinal gas, bloating, microscopic colitis, inflammatory bowel disease and traveler's diarrhea using colloidal bismuth subcitrate
AU719090B2 (en) Oral preparation for the prophylactic and therapeutic treatment of helicobacter sp. infection
AU590578B2 (en) Treatment of non-ulcer dyspepsia with bismuth salts
Hudson et al. Successful Helicobacter pylori eradication incorporating a one‐week antibiotic regimen
JPS6248623A (ja) 胃腸疾患の治療のための医薬組成物
JP4981208B2 (ja) 感染性潰瘍又は胃炎に対するタウロリジン及び／又はタウルルタム
JP2003500451A5 (fr)
WO1995032720A1 (fr) Composition pour traiter des troubles gastro-intestinaux
JPH0692850A (ja) 胃腸障害治療薬
US4689229A (en) Gastrointestinal compositions
US8241683B2 (en) Decolonizing agent for helicobacter pylori
RU2737891C2 (ru) Применение антибиотиков со специфичными терапевтическими активностями в комбинации с одновременным применением лактобацилл и/или бифидобактерий с непередающейся устойчивостью к антибиотикам, имеющих такое же терапевтическое показание
JPH07242560A (ja) 抗菌剤
KR100375342B1 (ko) 위장 질환 개선을 위한 천연 항균물질 조성물
JP2012522019A (ja) 腸管前処置のための組成物およびその使用方法
EP0715520B1 (fr) Utilisatioin d'une suspension a base de gel de sucralphate comme antiacide
TWI887550B (zh) 可預防或治療幽門螺旋桿菌感染的乳酸菌菌株及其相關應用
RU2315596C1 (ru) Фармацевтическая композиция, обладающая антацидным и репаративным действием, получение и применение
AU2540588A (en) Improved method for treatment of gastrointestinal disorders
RU2352346C2 (ru) СПОСОБ ЛЕЧЕНИЯ ЯЗВЕННОЙ БОЛЕЗНИ ЖЕЛУДКА И ДВЕНАДЦАТИПЕРСТНОЙ КИШКИ, АССОЦИИРОВАННОЙ С Helicobacter pylori

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA